Effect of Corticotropin-Releasing Hormone Antagonist on Oestrogen-Dependent Glucoprivic Suppression of Luteinizing Hormone Secretion in Female Rats

S. Tsukahara, H. Tsukamura, D. L. Foster* and K.-I. Maeda
School of Agricultural Sciences, Nagoya University, Nagoya 464-0814, Japan.
*Reproductive Sciences Program, Departments of Obstetrics and Gynecology and Biology, University of Michigan, Ann Arbor, Michigan 48109-0404, USA.

Key words: corticotropin-releasing hormone, luteinizing hormone, 2-deoxyglucose, oestrogen, glucose availability.

Abstract
Pharmacological reduction of glucose availability with 2-deoxyglucose (2DG) suppresses pulsatile luteinizing hormone (LH) secretion in rats and growth-retarded lambs. Gonadal steroids enhance the glucoprivic suppression of LH secretion in rats. The present study determined if corticotropin-releasing hormone (CRH) plays a role in mediating oestrogen-dependent and -independent glucoprivic suppression of LH secretion. The study was conducted in ovariectomized (OVX) rats some of which received Silastic implants containing oestradiol-17β (OE2) dissolved in peanut oil at 20 μg/ml to produce a physiological plasma level of OE2 (30 pg/ml). Seven days after ovariectomy, the rats were stereotaxically implanted with a guide cannula into the third cerebral ventricle. Seven days later, blood samples were collected through an indwelling atrial cannula every 6 min for 3 h for LH pulse determination. After the first hour of blood sampling, a CRH antagonist, [d-Phe12, Nle21,38]hCRF-(21–41), or vehicle was injected into the third cerebral ventricle through the implanted cannula before 2DG administration through the indwelling atrial cannula. Pulsatile LH secretion was suppressed by 2DG (200 mg/kg b.w.) in the vehicle-treated rats bearing OE2 implants. The CRH antagonist (5.65 nmol) blocked the suppressive effect of 2DG on pulsatile LH secretion in the OE2-treated OVX animals. On the other hand, in the absence of oestrogen, the effect of a twice greater dose of 2DG (400 mg/kg b.w.) was not blocked by five times greater amount of CRH antagonist (28.3 nmol). These results suggest the mechanisms mediating glucoprivic suppression of LH secretion involve two components: one is oestrogen-dependent and the other oestrogen-independent. CRH may be involved in the oestrogen-dependent component of glucoprivic suppression of LH secretion but not the oestrogen-independent one.

The reduction of glucose availability is considered as one of the factors suppressing LH secretion under nutritional stress. Pharmacological reduction of glucose availability with 2-deoxyglucose (2DG) interrupts oestrous cyclicity in Syrian hamsters (1), and suppresses pulsatile luteinizing hormone (LH) secretion in lambs (2) and rats (3–5). Our previous study in female rats suggested that fasting activates the catecholaminergic input from the solitary tract nucleus to the paraventricular nucleus (PVN) to stimulate corticotropin-releasing hormone (CRH) release and then suppress gonadotropin-releasing hormone/LH secretion (6). It is thought that noradrenergic input to the PVN suppresses LH secretion through a CRH-dependent pathway in the presence of oestrogen, or through a CRH-independent pathway in the absence of this steroid. This is because local noradrenaline injection into the PVN suppresses LH secretion through stimulating CRH release in oestradiol-17β (OE2)-primed ovariectomized (OVX) rats, but it causes a transient suppression that is not mediated by CRH in OVX animals (7). Accordingly, we propose that fasting stress suppresses LH secretion in a CRH-dependent/oestrogen-dependent manner and a CRH-independent/oestrogen-independent manner.
Glucose availability is sensed by a glucose sensitive area in the lower brain stem, such as the area postrema and the information is sent to the PVN via the noradrenergic pathway. The existence of this pathway, which may be similar to that mediating fasting-induced suppression of LH secretion, is based on the following evidence: central administration of 2DG suppresses pulsatile LH secretion in rats (3) and lambs (2); lesions of the area postrema, a circumventricular organ in the caudal brain stem, prevent the effect of 2DG on normal oestrous cyclicity in Syrian hamsters (8); glucoprivation stimulates noradrenaline release in the PVN; and the blockade of catecholamine synthesis in the PVN nullifies the glucoprivic suppression of LH secretion (5). In addition, 2DG suppresses LH secretion in the presence or absence of sex steroids in both genders, with steroid-treated animals being more sensitive to the glucoprivation (4). In this regard, glucoprivic suppression of LH secretion may be mediated by a CRH-dependent and/or CRH-independent mechanism.

The present study was designed to determine whether CRH mediates the oestrogen-dependent or oestrogen-independent 2DG effect on pulsatile LH secretion in female rats.

Results

Figure 1a shows the representative profiles of plasma LH levels in 2E2-treated OVX individuals, which were injected with CRH antagonist (5.65 nmol) or vehicle into the third cerebral ventricle before 2DG administration at the dose of 200 mg/kg b.w. In the vehicle-treated animals, 2DG transiently suppressed pulsatile LH secretion. In contrast, pulsatile LH secretion was not blocked by 2DG treatment when the animals received an intracerebroventricular (i.c.v.) injection of the CRH antagonist. There was significant (P < 0.05) difference in the percent change in mean plasma LH concentration before and after 2DG treatment between the vehicle- and CRH antagonist-injected groups (Mann-Whitney U-test, Fig. 1b).

Figure 2a shows representative profiles of plasma LH levels in the OVX individuals treated with 2DG (400 mg/kg b.w.) after i.c.v. injection of a CRH antagonist (28.3 nmol) or vehicle. Pulsatile LH secretion was suppressed by 2DG in both vehicle-injected and CRH antagonist-injected groups. Pretreatment of animals with the CRH antagonist at 28.3 nmol did not affect the 2DG-induced suppression of LH pulses. There was no significant difference in the percent change in mean plasma LH concentration between the groups (Mann-Whitney U-test, Fig. 2b).

Discussion

Our previous study revealed that oestrogen enhances the 2DG effect to inhibit pulsatile LH secretion, because 2DG...
Glucoprivic suppression of luteinizing hormone suppresses LH secretion at 200 mg/kg b.w. in steroid-treated rats, but not in females without steroid treatment (4). In the present study, therefore, the minimum doses of 2DG were chosen to induce suppression of LH secretion in both OVX and OEST-treated OVX animals according to the aforementioned result. The CRH antagonist at the larger dose (28.3 nmol) was ineffective in preventing the glucoprivic suppression of LH release in OVX animals. This dose of the antagonist in OVX rats was five times as much as that was used in OEST-primed OVX rats in the present study. It is reported that [d-Phe^{12}, Nle^{21,38}]hCRF-(21–41) used in the present study is approximately 15 times more potent than that of α-helical CRF-(9–41) in terms of antagonizing corticotropin release (9). α-Helical CRF-(9–41) at 26 nmol i.c.v. injection into the third cerebral ventricle was effective in preventing the suppression of LH release in rats that had fasted for 48 h (6). Therefore, the doses of 2DG and CRH-antagonist chosen in the present study are based on the previous experiments and seem to be within reasonable ranges to evaluate their effect.

In the present study, 2DG suppressed LH secretion in both OVX and OEST-treated OVX rats, but this effect was blocked by the CRH antagonist at a lower dose in OEST-treated OVX animals. This raises the possibility that reduced glucose availability suppresses LH secretion through stimulating CRH release in the presence of oestrogen, but through another pathway in the absence of oestrogen. Several lines of evidence indicate that oestrogen is involved in activating CRH production or release in the PVN, since the primary transcript for CRH was increased by endotoxin lipopolysaccharide and c-fos mRNA was increased in CRH-immunoreactive cells on the morning of pro-oestrus in female rats (10). Both corticotropin release and corticosterone release in response to restraint stress were greater in pro-oestrus compared with other phases of oestrous cycle and these responses were also higher in OEST-treated OVX rats than OVX rats (11). Taken together, the increased sensitivity to 2DG in the presence of oestrogen might be due to the activation of CRH production or release by oestrogen. On the other hand, the 2DG may not stimulate CRH to the level sufficient to suppress LH secretion in the absence of oestrogen and, therefore, the higher amount of 2DG could suppress LH secretion through a pathway other than CRH release. Another possibility is that opioidergic system mediating CRH action may be modulated by oestrogen, since the suppressive effect of CRH on LH secretion is mediated through opioidergic system (12, 13) and naloxone-induced LH secretion is dependent upon the presence of gonadal steroids in rats (14, 15).

Arginine vasopressin (AVP) has been reported to mediate suppressive effects of stress on LH secretion (16), and to play a role in compensation for the CRH deficiency (17). In addition, AVP and CRH synergistically stimulate corticotropin release from the isolated perfused anterior pituitary gland.

Fig. 2. (a) Representative profiles of plasma LH concentrations in OVX rats, which were injected with CRH antagonist (28.3 nmol) or vehicle before 2DG (400 mg/kg b.w.) treatment at arrows. Arrowheads indicate peaks of LH pulses. (b) Per cent change in mean plasma LH concentrations before and after 2DG treatment in OVX rats. Numbers in columns indicate the number of animals used in each group. See Fig. 1 for details.

Blood samples were centrifuged at 12,000 r.p.m. for 10 min, and plasma was kept at 2°C plasma OE

Materials and methods

Animals

Adult female Wistar-Imamichi strain rats weighing 230-275 g were used. Animals were kept in a light (14 h light: 10 h dark, lights on at 0500 h) and temperature (22 ± 2°C)-controlled room with free access to water and food (Labo-MR-stock, Nihon Nosan Kogyo Co., Yokohama, Japan). Animals showing estrous cycles were bilaterally OVX. Some animals were implanted with Silastic tubing (inner diameter, 1.5 mm; outer diameter, 3.0 mm; length, 25 mm; Dow Corning, Midland, MI, USA) containing OE2 (Sigma Chemical Co., St. Louis, MO, USA) dissolved in peanut oil at 20 μg/ml immediately after ovariecotomy to produce physiological plasma OE2 levels (19).

Brain surgery

One week after the ovariecotomy, a stainless steel guide cannula (22 gauge; Plastic Products Co., Roanoke, VA, USA) was stereotaxically implanted into the third cerebral ventricle. Stereotaxic coordinates of the tip of i.c.v. cannula was 0.8 mm caudal and 7.0 mm ventral to the bregma at the midline according to a rat brain atlas (20). Animals were allowed to recover from brain surgery for 1 week before blood sampling.

Drugs

2DG (Sigma) was dissolved with saline at the concentration of 250 or 125 μg/μl for administration to OVX (400 mg/kg b.w. 2DG) or OE2-primed OVX (200 mg/kg b.w. 2DG) animals, respectively. The 2DG doses chosen for each group in the present study are the minimum effective doses to suppress LH secretion according to our previous study (4). The CRH antagonist [N-Phe12, Nle13,18]-corticotropin-releasing hormone (Salk Institute, La Jolla, CA, USA) was used for the present study. The CRH antagonist was dissolved in 10 μl of saline and for i.c.v. injection to the OVX (28.3 nmol antagonist) or OE2-primed OVX (5.65 nmol antagonist) rats, respectively. All reagents were prepared immediately before use.

Experimental protocol

One day before blood sampling, a silicone cannula (inner diameter, 0.5 mm; outer diameter, 1 mm; Shin-Etsu Polymer Co., Tokyo, Japan) was inserted into the right atrium through the right jugular vein. Blood samples (100 μl) were taken from the freely-moving animals every 6 min for 3 h. An equivalent volume of rat red blood cells taken from donor animals was suspended in saline and replaced through the cannula after each blood sampling.

The CRH antagonist or vehicle was infused into the third cerebral ventricle through an inner cannula (28 gauge; Plastic Products Co, Roanoke, VA, USA) inserted into the guide cannula with a microsyringe at 2.5 μl/min for 4 min before the 2DG injection. Four hundred μl of 2DG solution were administered through the atrial catheter after the first hour of blood sampling. Blood samples were centrifuged at 12,000 r.p.m. for 10 min, and plasma was kept at −30°C until assayed for LH.

Hormone assay

Plasma LH concentrations were determined by a double antibody RIA with a rat LH RIA kit provided by the National Hormone and Pituitary Program (Baltimore, MD, USA) and results were expressed in terms of the reference preparation NIHDDK rat LH RP-3. The least detectable level of LH was 0.156 ng/ml for 50 μl of plasma. The intra- and interassay coefficients of variation were 6.71% at level of 0.76 ng/ml and 11.2% at level of 1.26 ng/ml, respectively.

Statistical analysis

LH pulses were identified by the PULSAR computer program (21). The criteria for LH pulse detection have been previously described (22). Per cent changes in mean plasma LH concentration before and after 2DG treatment were determined by calculating the ratio of the difference in mean plasma LH concentrations between the pre- and post-2DG treatment periods to the mean LH concentration before 2DG treatment in individual animals. Statistical differences of the percent change in mean plasma LH concentration between vehicle- and CRH antagonist-injected groups were analysed by the Mann-Whitney U-test.

Acknowledgements

We are grateful to the National Hormone and Pituitary Program for the LH assay kit, the Imamichi Institute for Animal Reproduction for supplying the animals, Dr W. Vale for providing the CRH antagonist, Drs G. R. Merriam and K. W. Wachter for the PULSAR computer program, and Y. Niwa for her technical assistance. The RIA and LH pulse analysis were performed at the Nagoya University Radiosotope Centre and the Nagoya University Computer Centre, respectively. This work was supported in part by Grants-in-Aid (nos 08660342 and 10460131) to H. T. and K. M.; a Grant-in-Aid for International Scientific Research (Joint Research No. 09044215) to K. M.; a Research Fellowship of the Japan Society for the Promotion of Science for Young Scientists (no. 80003249) to D. T. from the Ministry of Education, Science, Sports and Culture, Japan; and the U.S-Japan Cooperative Science Program to D. L. F. and K. M. from NSF and JSPS.

Accepted 17 August 1998

References

11 Viau V, Meaney MJ. Variations in the hypothalamic-pituitary-adrenal